Datapoint: UCB to Acquire Zogenix
Biopharma company UCB last week entered a deal to acquire Zogenix, the manufacturer of epilepsy drug Fintepla. For the treatment of epilepsy, Fintepla holds covered or better status for 87% of all insured lives under the pharmacy benefit. 11% of all covered lives have preferred access to Fintepla.
SOURCE: MMIT Analytics, as of 1/24/22